(Alliance News) - Faron Pharmaceuticals Oy on Monday noted data which showed "significant survival benefit" in patients responding to cancer treatment bexmarilimab.
Faron shares surged 12% at 350.00 pence each in London on Monday.
Part two of the trial indicated the treatment reduced risk of death by 88%.
Faron is a Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
In the trial, bexmarilimab is being investigated as a potential monotherapy in patients with solid tumours who have exhausted all treatment options.
Gastric cancer has become the sixth tumour type to show early signs of clinical efficacy, the company noted.
The company has previously reported early signs of clinical efficacy in five of the 10 solid tumour cohorts - colorectal cancer, cutaneous melanoma, ovarian cancer, hepatocellular cancer and cholangiocarcinoma.
Faron said additionally that the study's data monitoring committee recommended increasing the dosing frequency in all cohorts showing early clinical benefits.
Chief Executive Markky Jalkanen said: "This is very exciting data supporting bexmarilimab's unique mechanism of action and adding to the accumulating evidence of bexmarilimab's broad potential across a range of hard-to-treat cancers. The early observations of survival benefit and the stark contrast in progression of disease among patients who do not respond to bexmarilimab therapy show the clinical significance of Clever-1 as immunotherapy target and the potential patient benefit when its immune-suppressive control is removed. We look forward to gathering further data from these patient cohorts to support the design of our pivotal trials for bexmarilimab."
By Greg Roxburgh; gregroxburgh@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)